Formoterol fumerate + fenoterol/ipratropium bromide
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Bronchial Obstruction, Asthma
Conditions
Acute Bronchial Obstruction, Asthma
Trial Timeline
Mar 1, 2007 → Sep 1, 2008
NCT ID
NCT00460577About Formoterol fumerate + fenoterol/ipratropium bromide
Formoterol fumerate + fenoterol/ipratropium bromide is a approved stage product being developed by Novartis for Acute Bronchial Obstruction, Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00460577. Target conditions include Acute Bronchial Obstruction, Asthma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00460577 | Approved | Completed |
Competing Products
20 competing products in Acute Bronchial Obstruction, Asthma